Clear Search

Showing 2 results for “Obesity; tirzepatide” published 2023.

November 2023

Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity: the SURMOUNT-3 Phase 3 Trial

Nat Med. 2023; online ahead of print DOI: 10.1038/s41591-023-02597-w

The use of antiobesity medications following intensive lifestyle intervention has been proposed as a strategy to induce additional weight reduction (which may be needed to achieve optimal control of obesity-related complications) or, at a minimum, to prevent weight regain. The effects of tirzepatide, the dual GIP and GLP-1RA, on weight reduction after successful intensive lifestyle intervention are unknown.

more…

June 2023

Efficacy and Safety of Tirzepatide for Treatment of Overweight or Obesity. A Systematic Review and Meta-analysis

Int J Obes (Lond). 2023. DOI: 10.1038/s41366-023-01321-5

 This systematic review and meta-analysis aimed to assess the efficacy and safety of tirzepatide for weight loss in patients with overweight or obesity.

more…